Share This Article:

Assessment of Insulin Resistance and Insulin Growth Factor-1 in Egyptian Patients with Chronic Hepatitis C

DOI: 10.4236/ojemd.2011.11001    4,337 Downloads   10,293 Views   Citations

ABSTRACT

Introduction: Insulin resistance (IR) is documented in patients with chronic hepatitis C(CHC), plays an important factor in disease progression and predicting poor response to treatment. In chronic liver disease, levels of insulin-like growth factor-1 (IGF-1) were correlated with IR. Aim: To evaluate IR and serum levels of IGF-1 in Egyptian patients with CHC after anti-viral therapy. Patients and Methods: Forty biopsy-proven, non-diabetic, CHC patients, who received combined IFN/ribavirin therapy, in addition to 10 healthy controls were studied. Serum levels of IGF-1, growth hormone (GH) were measured and HOMA-IR(homeostasis model assessment of IR), body mass index (BMI) were calculated. Baseline data, retrieved from patients’ files before initiation of therapy, together with response to antiviral therapy were analyzed with respect to the measured variables. Results: All patients possessed a significant higher HOMA-IR score (p = 0.02), GH levels (p < 0.001) and blood glucose levels (p < 0.001) than controls while significantly lower levels of IGF-1 were found in patients (p = 0.008)with no significant difference between responders and non-responders as regards the previously mentioned variables. HOMA-IR score was significantly correlated with GH levels, p = 0.003 and with IGF-1 levels in both responders and non responders. Low IGF-1 levels were associated with increase in fibrosis stages and were significantly correlated with insulin(r = –0.499, p = 0.001). Conclusion: CHC patients exhibit an increased HOMA-IR score reflecting the existence of IR irrespective of treatment response. Low IGF-1 levels were associated with advanced stages of fibrosis and thus could contribute to the progression of hepatic fibrosis in CHC.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

I. Kostandi, M. Bahgat, N. Zayed and L. Rashed, "Assessment of Insulin Resistance and Insulin Growth Factor-1 in Egyptian Patients with Chronic Hepatitis C," Open Journal of Endocrine and Metabolic Diseases, Vol. 1 No. 1, 2011, pp. 1-8. doi: 10.4236/ojemd.2011.11001.

References

[1] M. Romero-Gómez, M. Del Mar Viloria, R. J. Andrade, J. Salmerón, M. Diago, C. M. Fernández-Rodríguez, R. Corpas, M. Cruz, L. Grande, L. Vázquez, P. Munoz-De-Rueda, P. López-Serrano, A. Gila, M. L. Gutiérrez, Pérez C, A. Ruiz-Extremera, E. Suárez and J. Castillo, “Insulin Resistance Impairs Sustained Response Rate to Peginterferon plus Ribavirin in Chronic Hepatitis C Patients,” Gastroenterology, Vol. 128, No. 3, 2005, pp. 636-641. doi:10.1053/j.gastro.2004.12.049
[2] F. Imazeki, O. Yokosuka, K. Fukai, T. Kanda, H. Kojima and H. Saisho, “Prevalence of Diabetes Mellitus and Insulin Resistance in Patients with Chronic Hepatitis C: Comparison with Hepatitis B Virus-Infected and Hepatitis C Virus-Cleared Patients,” Liver International, Vol. 28, No. 3, 2008, pp. 355-362. doi:10.1111/j.1478-3231.2007.01630.x
[3] R. Moucari, T. Asselah, D. Cazals-Hatem, H. Voitot, N. Boyer, M. P. Ripault, R. Sobesky, M. Martinot-Peignoux, S. Maylin, M. H. Nicolas-Chanoine, V. Paradis, M. Vidaud, D. Valla, P. Bedossa and P. Marcellin, “Insulin Resistance in Chronic Hepatitis C: Association with Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis,” Gastroenterology, Vol. 134, No. 2, 2008, pp. 416-423. doi:10.1053/j.gastro.2007.11.010
[4] E. R. Parise and A. C. Oliveira, “Insulin Resistance in Chronic Hepatitits C,” Arquivos de Gastroenterologia, Vol. 44, No. 2, 2007, pp. 178-184. doi:10.1590/S0004-28032007000200017
[5] S. A. Harrison, “Insulin Resistance among Patients with Chronic Hepatitis C: Etiology and Impact on Treatment,” Clinical Gastroenterology and Hepatology, Vol. 6, No. 8, 2008, pp. 864-876. doi:10.1016/j.cgh.2008.03.024
[6] M. Y. Sheikh, J. Choi, I. Qadri, J. E. Friedman and A. J. Sanyal, “Hepatitis C Virus Infection: Molecular Pathways to Metabolic Syndrome,” Hepatology, Vol. 47, No. 6, 2008, pp. 2127-2133. doi:10.1002/hep.22269
[7] L. Fartoux, A. Poujol-Robert, J. Guéchot, D. Wendum, R. Poupon and L. Serfaty, “Insulin Resistance is a Cause of Steatosis and Fibrosis Progression in Chronic Hepatitis C,” Gut, Vol. 54, No. 7, 2005, pp. 1003-1008. doi:10.1136/gut.2004.050302
[8] J. M. Hui, A. Sud, G. C. Farrell, P. Bandara, K. Byth, J. G. Kench, G. W. Mccaughan and J. George, “Virus-Induced Insulin Resistance May Be a Mechanism for Fibrogenesis in Chronic Hepatitis C Virus Infection,” Gastroenterology, Vol. 125, No. 6, 2003, pp. 1695-1704. doi:10.1053/j.gastro.2003.08.032
[9] J. M. Petit, J. B. Bour, C. Galland-Jos, et al., “Risk Factors for Diabetes Mellitus and Early Insulin Resistance in Chronic Hepatitis C,” Journal of Hepatology, Vol. 35, No. 2, 2001, pp. 279-283. doi:10.1016/S0168-8278(01)00143-X
[10] R. D’Souza, C. A. Sabin and G. R. Foster “Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy,” The American Journal of Gastroenterology, Vol. 100, No. 7, 2005, pp. 1509-1515. doi:10.1111/j.1572-0241.2005.41403.x
[11] H. Poustchi, F. Negro, J. Hui, I. H. Cua, L. R. Brandt, J. G. Kench and J. George, “Insulin Resistance and Response to Therapy in Patients Infected with Chronic Hepatitis C Virus Genotypes 2 and 3,” Journal of Hepatology, Vol. 48, No. 1, 2008, pp. 28-34. doi:10.1016/j.jhep.2007.07.026
[12] A. Picardi, U. V. Gentilucci, E. M. Zardi, D. Caccavo, T. Petitti, S. Manfrini, P. Pozzilli and A. Afeltra, “TNF-Alpha and Growth Hormone Resistance in Patients with Chronic Liver Disease,” Journal of Interferon & Cytokine Research, Vol. 23, No. 5, 2003, pp. 229-235. doi:10.1089/107999003321829944
[13] M. Coculescu, D. Niculescu, R. Lichiardopol and M. Purice, “Insulin Resistance and Insulin Secretion in Non-Diabetic Acromegalic Patients,” Experimental and Clinical Endocrinology & Diabetes, Vol. 115, No. 5, 2007, pp. 308-316. doi:10.1055/s-2007-961797
[14] E. Succurro, F. Andreozzi, A. Sciaqua, M. L. Hribal, F. Perticone and G. Sesti, “Reciprocal Association of Plasma IGF-1 and Interleukin-6 Levels with Cardiometabolic Risk Factors in Nondiabetic Subjects,” Diabetes Care, Vol. 31, No. 9, 2008, pp. 1886-1888. doi:10.2337/dc08-0553
[15] G. Morali, A. B. Shitrit, M. Eran, S. Freier, C. Reinus and D. Braverman, “Hepatic Production of Insulin-Like Growth Factors in Normal and Diseased Liver,” Hepato-Gastroenterology, Vol. 52, No, 65, 2005, pp. 1511-1515.
[16] F. C. Goetz, “A Simple Immunoassay for Insulin: Application to Human and Dog Plasma,” The Journal of Clinical Endocrinology & Metabolism, Vol. 23, No. 12, 1963, pp. 1237-1246. doi:10.1210/jcem-23-12-1237
[17] E. Bonora, G. Targher, M. Alberiche, R. C. Bonadonna, F. Saggiani, M. B. Zenere, T. Monauni and M. Muggeo, “Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin Sensitivity: Studies in Subjects with Various Degrees of Glucose Tolerance and Insulin Sensitivity,” Diabetes Care, Vol. 23, No. 1, 2000, pp. 57-63. doi:10.2337/diacare.23.1.57
[18] C. A. Burtis and E. R. Ashwood, “Tietz Fundamentals of Clinical Chemistry,” 4th Edition, W. B. Saunders Company, Philadelphia, 1996.
[19] E. M. Rutanen and F. Pekonen, “Assays for IGF Binding Proteins,” Acta Endocrinologica (Copenhagen), Vol. 124, Supplement. 2, 1991, pp. 70-73.
[20] S. Radhakrishnan, P. Abraham, S. Raghuraman, G. T. John, P. P. Thomas and C. K. Jacob, et al., “Role of Molecular Techniques in the Detection of HBV DNA and HCV RNA among Renal Transplant Recipients in India,” Indian Journal of Medical Research, Vol. 111, 2000, pp. 204-211.
[21] A. K. Panigrahi, S. K. Nanda, R. K. Dixit, S. K. Acharya, A. J. Zuckerman and S. K. Panda, “Diagnosis of Hepatitis C Virus-Associated Chronic Liver Disease in India: Comparison of HCV Antibody Assay with a Polymerase Chain Reaction for the 5’ Noncoding Region,” Journal of Medical Virology, Vol. 44, No. 2, 1994, pp. 176-179. doi:10.1002/jmv.1890440211
[22] P. Bedossa and T. Poynard, “An Algorithm for the Grading of Activity in Chronic Hepatitis C. The METAVIR Cooperative Study Group,” Hepatology, Vol. 24, No. 2, 1996, pp. 289-293. doi:10.1002/hep.510240201
[23] A. Picardi, D. D’Avola, U. V. Gentilucci, G. Galati, E. Fiori, S. Spataro and A. Afeltra, “Diabetes in Chronic Liver Disease: From Old Concepts to New Evidence,” Diabetes/Metabolism Research and Reviews, Vol. 22, No. 4, 2006, pp. 274-283. doi:10.1002/dmrr.636
[24] W. P. Pimenta, M. L. Santos, N. S. Cruz, F. F. Aragon, C. R. Padovani and J. E. Gerich, “Insulin Secretion, Insulin Sensitivity, and Hepatic Insulin Extraction in First-Degree Relatives of Type 2 Diabetic Patients,” Brazilian Journal of Medical and Biological Research, Vol. 36, No. 3, 2003, pp. 301-308. doi:10.1590/S0100-879X2003000300003
[25] S. Decock, C. Verslype and J. Fevery, “Hepatitis C and Insulin Resistance: Mutual Interactions. A Review,” Acta Clinica Belgica, Vol. 62, No. 2, 2007, pp. 111-119.
[26] R. Narita, S. Abe, Y. Kihara, T. Akiyama, A. Tabaru and Otsuki M, “Insulin Resistance and Insulin Secretion in Chronic Hepatitis C Virus Infection,” Journal of Hepatology, Vol. 41, No. 1, 2004, pp. 132-138. doi:10.1016/j.jhep.2004.03.020
[27] V. Mello, T. Cruz, G. Nunez, M.T. Simoes, F. Ney-Oliveira, H. Braga, C. Araújo, S. Cunha, M. I. Schinoni, M. Cruz and R. Parana, “Peripheral Insulin Resistance during Treatment of Chronic Hepatitis C with Peguilated Interferon plus Ribavirin,” Journal of Medical Virology, Vol. 78, No. 11, 2006, pp. 1406-1410. doi:10.1002/jmv.20712
[28] C. Giordanino, E. Bugianesi, A. Smedile, A. Ciancio, M. L. Abate, A. Olivero, R. Pellicano, M.Cassader, R. Gambino, S. Bo, G. Ciccone, M. Rizzetto and G. Saracco, “Incidence of Type 2 Diabetes Mellitus and Glucose Abnormalities in Patients with Chronic Hepatitis C Infection by Response to Treatment: Results of a Cohort Study,” The American Journal of Gastroenterology, Vol. 103, No. 10, 2008, pp. 2481-2487. doi:10.1111/j.1572-0241.2008.02002.x
[29] M. Romero-Gómez, C. Fernandez-Rodriguez, S. Alonso, J. A. Pons, P. López-Serrano, M. L. Gutiérrez, C. Pérez, R. Temi?o, P. García, L. Grande and M. Diago. “Sustained Response in Chronic Hepatitis C Reduces the Risk to Develop Impaired Fasting Glucose and/or Diabetes Type 2,” Journal of Hepatology, Vol. 44, Supplement. 2, 2006, p. 204.
[30] A. J. Sanyal, N. Chand, K. Comar and F. Mirshahi, “Hyperinsulinemia Blocks the Inhibition of Hepatitis C Virus (HCV) Replication by Interferon: A Potential Mechanism for Failure of Interferon Therapy in Subjects with HCV and Nonalcoholic Fatty Liver Disease,” Hepatology, Vol. 40, Supplement. 1, 2004, p. 179.
[31] H. Noto and P. Raskin, “Hepatitis C Infection and Diabetes,” Journal of Diabetes and Its Complications, Vol. 20, No. 2, 2006, pp. 13-20. doi:10.1016/j.jdiacomp.2006.01.001
[32] T. C. Schreuder, H. C. Gelderblom, C. J. Weegink, D. Hamann, H. W. Reesink, J. H. Devries, J. B. Hoekstra and P. L. Jansen, “High Incidence of Type 1 Diabetes Mellitus during or Shortly after Treatment with Pegylated Interferon Alpha for Chronic Hepatitis C Virus Infection,” Liver International, Vol. 28, No. 1, 2008, pp. 39-46. doi:10.1111/j.1478-3231.2007.01610.x
[33] I. J. Hickman, A. D. Clouston, G. A. Macdonald, D. M. Purdie, J. B. Prins, S. Ash, J. R. Jonsson and E. E. Powell, “Effect of Weight Reduction on Liver Histology and Biochemistry in Patients with Chronic Hepatitis C,” Gut, Vol. 51, No. 1, 2002, pp. 89-94. doi:10.1136/gut.51.1.89
[34] M. Romero-Gómez, V. M. Castellano-Megias, L. Grande, J. A. Irles, M. Cruz, M. C. Nogales, J. C. Alcón and A. Robles, “Serum Leptin Levels Correlate with Hepatic Steatosis in Chronic Hepatitis C,” The American Journal of Gastroenterology, Vol. 98, No. 5, 2003, pp. 1135-1141. doi:10.1016/S0002-9270(03)00185-0
[35] A. Lecube, C. Hernández, J. Genescà, J. I. Esteban, R. Jardí and R. Simó, ‘High Prevalence of Glucose Abnormalities in Patients with Hepatitis C Virus Infection: A Multivariate Analysis Considering the Liver Injury,” Diabetes Care, Vol. 27, No. 5, 2004, pp. 1171-1175. doi:10.2337/diacare.27.5.1171
[36] V. Ratziu, M. Munteanu, F. Charlotte, L. Bonyhay and T. Poynard, “Fibrogenic Impact of High Serum Glucose in Chronic Hepatitis C,” Journal of Hepatology, Vol. 39, No. 6, 2003, pp. 1049-1055. doi:10.1016/S0168-8278(03)00456-2
[37] V. Paradis, D. Dargere, M. Vidaud, et al., “Expression of Connective Tissue Growth Factor in Experimental Rat and Human Liver Fibrosis,” Hepatology, Vol. 30, No. 4, 1999, pp. 968-976. doi:10.1002/hep.510300425
[38] V. Paradis, G. Perlemuter, F. Bonvoust, et al., “High Glucose and Hyperinsulinemia Stimulate Connective Tissue Growth Factor Expression: A Potential Mechanism Involved in Progression to Fibrosis in Nonalcoholic Steatohepatitis,” Hepatology, Vol. 34, No. 4, 2001, pp. 738-744. doi:10.1053/jhep.2001.28055
[39] I. H. Cua, J. M. Hui, J. G. Kench and J. George, “Genotype-Specific Interactions of Insulin Resistance, Steatosis, and Fibrosis in Chronic Hepatitis C,” Hepatology, Vol. 48, No. 3, 2008, pp. 723-731. doi:10.1002/hep.22392
[40] T. Asselah, N. Boyer, M. C. Guimont, D. Cazals-Hatem, F. Tubach, K. Nahon, et al., “Liver Fibrosis is not Associated with Steatosis but with Necroinflammation in French Patients with Chronic Hepatitis C,” Gut, Vol. 52, No. 11, 2003, pp. 1638-1643. doi:10.1136/gut.52.11.1638
[41] G. Leandro, A. Mangia, J. Hui, P. Fabris, L. Rubbia-Brandt, G. Colloredo, et al., “The Relationship between Hepatic Steatosis, Inflammation and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data,” Gastroenterology, Vol. 130, No. 6, 2006, pp. 1636-1642. doi:10.1053/j.gastro.2006.03.014
[42] U. Pl?ckinger, D. Krüger, A. Bergk, V. Weich, B. Wiedenmann and T. Berg, “Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-Based Treatment,” The American Journal of Gastroenterology, Vol. 102, No. 12, 2007, pp. 2724-2731.
[43] J. B. Li, C. Y. Wang, J. W. Chen, Z. Q. Feng and H. T. Ma, “Expression of Liver Insulin-Like Growth Factor 1 Gene and Its Serum Level in Patients with Diabetes,” World Journal of Gastroenterology, Vol. 10, No. 2, 2004, pp. 255-259.
[44] A. Y. Kwan and M. L. Hartman, “IGF-I Measurements in the Diagnosis of Adult Growth Hormone Deficiency,” Pituitary, Vol. 10, No. 2, 2007, pp. 151-157. doi:10.1007/s11102-007-0028-8
[45] A. C. Moses, “Insulin Resistance and Type 2 Diabetes Mellitus: Is There a Therapeutic Role for IGF-1?” Endocrine Development, Vol. 9, 2005, pp. 121-134. doi:10.1159/000085762
[46] M. Abdel-Hamid, M. El-Daly, V. Molnegren, S. El-Kafrawy, S. Abdel-Latif, G. Esmat, G. T. Strickland, C. Loffredo, J. Albert and A. Widell, “Genetic Diversity in Hepatitis C Virus in Egypt and Possible Association with Hepatocellular Carcinoma,” Journal of General Virology, Vol. 88, No. 5, 2007, pp. 1526-1531. doi:10.1099/vir.0.82626-0
[47] M. Romero-Gómez, “Hepatitis C and Insulin Resistance: Steatosis, Fibrosis and Non-Response,” Revista Espa?ola de Enfermedades Digestivas, Vol. 98, No. 8, 2006, pp. 605-615.
[48] M. Romero-Gómez, “Insulin Resistance and Hepatitis C,” World Journal of Gastroenterology, Vol. 12, No. 44, 2006, pp. 7075-7080.
[49] S. Bondini and Z. M. Younossi, “Non-Alcoholic Fatty Liver Disease and Hepatitis C Infection,” Minerva Gastroenterol Dietol, Vol. 52, No. 2, 2006, pp. 135-143.
[50] S. B. Missiha, M. Ostrowski and E. J. Heathcote, “Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors,” Gastroenterology, Vol. 134, No. 6, 2008, pp. 1699-1714. doi:10.1053/j.gastro.2008.02.069
[51] V. G. Bain, K. D. Kaita, P. Marotta, E. M. Yoshida, M. G. Swain, R. J. Bailey, K. Patel, P. W. Cronin, E. Pulkstenis, J. G. McHutchison and G. M. Subramanian, “Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients,” Clinical Gastroenterology and Hepatology, Vol. 6, No. 6, 2008, pp. 701-706. doi:10.1016/j.cgh.2008.02.056

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.